Thomas R. Buch

Leipzig, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat.

Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat.

Journal: Neoplasia (New York, N.Y.)

Published: October 18, 2024

Vorinostat Treatment of Gastric Cancer Cells Leads to ROS-Induced Cell Inhibition and a Complex Pattern of Molecular Alterations in Nrf2-Dependent Genes.

Vorinostat Treatment of Gastric Cancer Cells Leads to ROS-Induced Cell Inhibition and a Complex Pattern of Molecular Alterations in Nrf2-Dependent Genes.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 10, 2024

The Histone Deacetylase Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2-Amplified Tumors and in Combination Therapies.

The Histone Deacetylase Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2-Amplified Tumors and in Combination Therapies.

Journal: Cancer research and treatment

Published: June 10, 2024

HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer.

HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer.

Journal: Biochemical pharmacology

Published: January 18, 2024

Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors.

Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors.

Journal: ChemMedChem

Published: December 15, 2021

Nrf2/Keap1-Pathway Activation and Reduced Susceptibility to Chemotherapy Treatment by Acidification in Esophageal Adenocarcinoma Cells.

Nrf2/Keap1-Pathway Activation and Reduced Susceptibility to Chemotherapy Treatment by Acidification in Esophageal Adenocarcinoma Cells.

Journal: Cancers

Published: April 13, 2021

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.

Journal: Cancers

Published: December 30, 2020

Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy.

Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy.

Journal: Cells

Published: December 29, 2020

SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells.

SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells.

Journal: International journal of molecular sciences

Published: November 26, 2020

Tyrosine-modified linear PEIs for highly efficacious and biocompatible siRNA delivery in vitro and in vivo.

Tyrosine-modified linear PEIs for highly efficacious and biocompatible siRNA delivery in vitro and in vivo.

Journal: Nanomedicine : nanotechnology, biology, and medicine

Published: October 20, 2020

Correction to: Restoration of MARCKS enhances chemosensitivity in cancer.

Correction to: Restoration of MARCKS enhances chemosensitivity in cancer.

Journal: Journal of cancer research and clinical oncology

Published: March 01, 2020

Restoration of MARCKS enhances chemosensitivity in cancer.

Restoration of MARCKS enhances chemosensitivity in cancer.

Journal: Journal of cancer research and clinical oncology

Published: November 18, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026